Cover Image
市場調查報告書

Panacea Pharmaceuticals, Inc. - 產品平台檢討

Panacea Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 199760
出版日期 內容資訊 英文 23 Pages
訂單完成後即時交付
價格
Back to Top
Panacea Pharmaceuticals, Inc. - 產品平台檢討 Panacea Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年06月24日 內容資訊: 英文 23 Pages
簡介

Panacea Pharmaceuticals, Inc.是總公司設在美國的製藥企業,進行創新治療藥及診斷用產品的藥物研發、開發及商品化。該公司的PAN-22為完全人類單株抗體,用於肝細胞癌症的治療藥。

本報告提供Panacea Pharmaceuticals, Inc. 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Panacea Pharmaceuticals, Inc. 的基本資料

  • Panacea Pharmaceuticals, Inc. 概要
  • 主要資訊
  • 企業資料

Panacea Pharmaceuticals, Inc. :R&D概要

  • 主要的治療範圍

Panacea Pharmaceuticals, Inc. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Panacea Pharmaceuticals, Inc. :開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Panacea Pharmaceuticals, Inc. :藥物簡介

  • PAN-22
  • PAN-622
  • PAN-811
  • Vaccine to Target HAAH for Oncology

Panacea Pharmaceuticals, Inc. :開發平台分析

  • 各標靶
  • 各分子類型
  • 各作用機制

Panacea Pharmaceuticals, Inc. :開發暫停中的計劃

Panacea Pharmaceuticals, Inc. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07158CDB

Summary

Global Markets Direct's, 'Panacea Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Panacea Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Panacea Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Panacea Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Panacea Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Panacea Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Panacea Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Panacea Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Panacea Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Panacea Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Panacea Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Panacea Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Panacea Pharmaceuticals, Inc. Snapshot
    • Panacea Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Panacea Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Panacea Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Panacea Pharmaceuticals, Inc. - Pipeline Products Glance
    • Panacea Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Panacea Pharmaceuticals, Inc. - Drug Profiles
    • PAN-22
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PAN-622
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PAN-811
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine to Target HAAH for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Panacea Pharmaceuticals, Inc. - Pipeline Analysis
  • Panacea Pharmaceuticals, Inc. - Pipeline Products by Target
  • Panacea Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
  • Panacea Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Panacea Pharmaceuticals, Inc. - Dormant Projects
  • Panacea Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Panacea Pharmaceuticals, Inc., Key Information
  • Panacea Pharmaceuticals, Inc., Key Facts
  • Panacea Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Panacea Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Panacea Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Panacea Pharmaceuticals, Inc. - Preclinical, 2015
  • Panacea Pharmaceuticals, Inc. - Discovery, 2015
  • Panacea Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Panacea Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Panacea Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Panacea Pharmaceuticals, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Panacea Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Panacea Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Panacea Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Panacea Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Panacea Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Panacea Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top